[Current Landscape of Sequential Treatment Strategy in Metastatic Urothelial Carcinoma] [0.03%]
转移性尿路上皮癌序贯治疗格局
Nozomi Hayakawa,Eiji Kikuchi
Nozomi Hayakawa
In 2024, enfortumab vedotin plus pembrolizumab(EV+P)and nivolumab plus gemcitabine/cisplatin(Nivo+GC)were approved as first-line therapies for metastatic urothelial carcinoma(mUC), marking a major shift in treatment strategy.EV+P, in partic...
[Current Development of Perioperative Immune Checkpoint Inhibitor Therapy for Muscle-Invasive Bladder Cancer] [0.03%]
肌层浸润性膀胱癌围手术期免疫检查点抑制剂治疗的现状与发展
Yuki Kita
Yuki Kita
Muscle-invasive bladder cancer(MIBC)carries a high risk of recurrence.The standard treatment has been cisplatin-based neoadjuvant chemotherapy(NAC)followed by radical cystectomy(RC), but nearly half of patients are cisplatin-ineligible and ...
[Evolving Pharmacotherapy for Bladder Cancer-From Non-Muscle-Invasive to Metastatic Disease-Development of Novel Therapies for BCG-Unresponsive NMIBC] [0.03%]
[膀胱癌的药物治疗进展——从非肌层浸润性到转移性疾病及卡介苗无效NMIBC新型疗法的开发]
Ryu Shigehisa,Satoshi Fukata,Keiji Inoue
Ryu Shigehisa
Bladder cancer is a common malignancy in the elderly, with approximately 75% of cases diagnosed as non-muscle-invasive bladder cancer(NMIBC).Although transurethral resection of bladder tumor(TURBT)is the standard initial treatment, recurren...
[Recent Progress in Novel Therapies for Non-Muscle Invasive Bladder Cancer] [0.03%]
新型非肌层浸润性膀胱癌治疗策略的研究进展
Takashi Kawahara
Takashi Kawahara
Non-muscle invasive bladder cancer(NMIBC)accounts for about 70% of bladder cancers, with most patients treated by TURBT followed by intravesical therapy according to recurrence risk.BCG is effective but BCG-unresponsive cases often require ...
Yoshinori Ito
Yoshinori Ito
Radiotherapy plays a central role in the management of esophageal cancer, encompassing definitive, neoadjuvant, and palliative indications.Recent advances in linear accelerator-based technologies, such as intensity-modulated radiotherapy(IM...
[A Case of Intrahepatic Cholangiocarcinoma Treated with Extended Right Hepatectomy with Partial Resection of the Inferior Vena Cava Following Laparoscopic Portal Vein Ligation] [0.03%]
腹腔镜肝门静脉结扎继发右半肝切除伴下腔静脉部分切除术治疗肝内胆管癌一例报告
Takeshi Aiyama,Tatsuhiko Kakisaka,Yoichi Yamamoto et al.
Takeshi Aiyama et al.
Introduction: Portal vein embolization(PVE)is a preoperative procedure that requires contrast media, making it contraindicated in patients with a history of contrast-induced anaphylaxis. We report a case of intrahepatic c...
[Pancreatic Tail Neuroendocrine Neoplasm with Metachronous Metastasis to the Lymph Nodes and Liver Consisting of Combined Neuroendocrine Tumors G2, G3, and Neuroendocrine Carcinoma-A Case Report] [0.03%]
胰尾神经内分泌肿瘤伴淋巴结及肝脏异时转移的混合性神经内分泌肿瘤G2、G3及神经内分泌癌1例报告
Tadashi Tsukamoto,Mikio Nanbara,Shinpei Eguchi et al.
Tadashi Tsukamoto et al.
A 50-year-old woman underwent distal pancreatectomy for pancreatic neuroendocrine neoplasm(NEN). Pathological analysis showed that the pancreatic tumor was composed of neuroendocrine tumors(NETs)G2 and G3, along with neuroendocrine cancer (...
[Intractable Hemorrhagic Duodenal Ulcer after Atezolizumab plus Bevacizumab Treatment for Hepatic Cancer with Lymph Node Metastases-A Case Report] [0.03%]
阿特朱单抗与贝伐珠单抗治疗肝癌伴淋巴结转移致难治性消化道出血1例报告
Tadashi Tsukamoto,Masaki Nishiyama,Tomohiro Kunimoto et al.
Tadashi Tsukamoto et al.
A 72-year-old woman with liver cirrhosis, diabetes, and parkinsonism was treated with atezolizumab plus bevacizumab (Atezo/Bev)for hepatic cancer and multiple lymph node metastases around the duodenum. After 2 doses of this treatment, alpha...
[A Case of R0 Resection after Neoadjuvant Chemotherapy for the Transverse Colon Cancer with Invasion of the Duodenum, Pancreas and Liver] [0.03%]
一例新辅助化疗后实现R0切除的十二指肠、胰腺及肝脏受侵横结肠癌病例报告
Nobuo Takiguchi,Masakazu Miyake,Shogo Yanagi et al.
Nobuo Takiguchi et al.
A 70s-year-old woman was diagnosed with advanced transverse colon cancer with an invasion of the duodenum, pancreas and liver. Pre-operative diagnosis was cT4b(the duodenum, pancreas and liver), N1b, M0, cStage Ⅲc. Neoadjuvant chemotherapy...
Yasuhiro Shoji,Yusuke Nakamura,Atsushi Tsuneda et al.
Yasuhiro Shoji et al.
The JSCCR Guidelines 2024 for the Treatment of Colorectal Cancer weakly recommend stent treatment as a bridge to surgery(BTS)for obstructive colorectal cancer in the context of curative surgical resection. We retrospectively examined the ba...